Patents by Inventor Wolfgang Woloszczuk
Wolfgang Woloszczuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9605068Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof for the diagnosis of heart disease, comprising the steps of providing a feline or canine sample, contacting the sample with at least one species-specific antibody for binding to at least one epitope of the respective species proBNP, determining the concentration of at least one fragment of proBNP, and diagnosing the animal with heart disease if the concentration is elevated compared to healthy subjects.Type: GrantFiled: February 27, 2009Date of Patent: March 28, 2017Assignee: THE ANTIBODY LAB GMBHInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Patent number: 9103839Abstract: The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.Type: GrantFiled: March 7, 2008Date of Patent: August 11, 2015Assignee: BIOMEDICA MEDIZINPRODUKTE GMBH & CO KGInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Patent number: 9005984Abstract: Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.Type: GrantFiled: February 27, 2009Date of Patent: April 14, 2015Assignee: Biomedica Medizinprodukte GmbH & Co KGInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Patent number: 8628973Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of providing a feline or canine sample, contacting the sample with at least one antibody which, when determining feline proBNP, or fragments thereof, respectively, binds to at least one epitope in the region comprising the amino acids 20 to 42 and/or in the region comprising the amino acids 57 to 80 of feline proBNP and, when determining canine proBNP, or fragments thereof, binds to at least one epitope in the region comprising the amino acids 20 to 86 of canine proBNP, and determining the presence and/or concentration of the feline or canine proBNP, or fragments thereof, present in the sample.Type: GrantFiled: September 8, 2005Date of Patent: January 14, 2014Assignee: Biomedica Medizinprodukte GmbH & Co KGInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Patent number: 8298774Abstract: The invention describes a method for diagnosing of septic complications in polytraumatised human or animal patients, said patients being free of traumatic brain injury, by determining the level of the C-type natriuretic peptide (CNP), its precursors or fragments thereof, especially the precursor of the C-type natriuretic peptide (NT-proCNP), in this patient and diagnosing the patient a having septic complications or being at risk of developing septic complications, if the level of CNP, its precursors or fragments thereof, especially NT-proCNP, is increased compared to normal levels.Type: GrantFiled: March 6, 2008Date of Patent: October 30, 2012Assignee: Biomedica Medizinprodukte GmbH & Co KGInventors: Soheyl Bahrami, Wolfgang Woloszczuk, Gerhard Hawa
-
Publication number: 20110189694Abstract: The present invention is directed to methods for the detection and diagnosis of bone and/or cartilage disorders, wherein the level of expression of a polypeptide in a test sample is measured by contacting the test sample with an antibody that specifically binds to said polypeptide and measuring the binding of said antibody to said test sample.Type: ApplicationFiled: October 22, 2009Publication date: August 4, 2011Applicant: BIOMARKER DESIGN FORSCHUNGS GMBHInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Publication number: 20100136590Abstract: The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.Type: ApplicationFiled: March 7, 2008Publication date: June 3, 2010Applicant: BIOMEDICA MEDIZINPRODUKTE GMBH & CO KGInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Publication number: 20090170138Abstract: Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 32 to 48 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed.Type: ApplicationFiled: February 27, 2009Publication date: July 2, 2009Inventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Publication number: 20090170137Abstract: Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed.Type: ApplicationFiled: February 27, 2009Publication date: July 2, 2009Inventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Publication number: 20090170136Abstract: Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.Type: ApplicationFiled: February 27, 2009Publication date: July 2, 2009Inventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Publication number: 20090170135Abstract: Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 20 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.Type: ApplicationFiled: February 27, 2009Publication date: July 2, 2009Inventors: Wolfgang Woloszczuk, Hawa Gerhard
-
Publication number: 20070161041Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of providing a feline or canine sample, contacting the sample with at least one antibody which, when determining feline proBNP, or fragments thereof, respectively, binds to at least one epitope in the region comprising the amino acids 20 to 42 and/or in the region comprising the amino acids 57 to 80 of feline proBNP and, when determining canine proBNP, or fragments thereof, binds to at least one epitope in the region comprising the amino acids 20 to 86 of canine proBNP, and determining the presence and/or concentration of the feline or canine proBNP, or fragments thereof, present in the sample.Type: ApplicationFiled: September 8, 2005Publication date: July 12, 2007Applicant: BIOMEDICA MEDIZINPRODUKTE GMBH & CO KGInventors: Wolfgang Woloszczuk, Gerhard Hawa